Dana-Farber physician-scientist David Braun honored as Next Gen Innovator

• Award recognizes “rising star” clinicians and researchers who specialize in solid tumors, hematologic malignancies and benign hematology

BOSTON – David A. Braun, MD, PhD, the John R. Svenson Fellow in Oncology at Dana-Farber/Brigham and Women’s Hospital, has been recognized by HemOnc Today as a Next Gen Innovator. This honor is given to early-career hematologists and oncologists who have advanced their field through innovative approaches in clinical and research settings.

HemOnc Today’s Next Gen Innovators include clinicians and researchers who specialize in solid tumors, hematologic malignancies, and benign hematology. Working under the mentorship of Catherine J. Wu, MD, chief of Dana-Farber Cancer Institute’s Division of Stem Cell Transplantation and Cellular Therapies, and Toni K. Choueiri, MD, director of the Lank Center for Genitourinary Oncology at Dana-Farber, Braun’s research focuses on understanding and improving immunotherapies in kidney cancer. His work utilizes immunogenomic approaches to elucidate mechanisms of response and resistance to existing immunotherapies, and to develop novel immune-based treatments. Together with Choueiri and Patrick A. Ott, MD, Braun is currently leading a clinical trial testing a personalized vaccine for the first time in patients with kidney cancer.

Launched in December 2017, Next Gen Innovators provide insights on studies presented at large-scale scientific meetings and on advances in their field which are then published in HemOnc Today.

“This honor presents a unique opportunity to exchange ideas with brilliant and energetic oncologists in diverse fields of study,” Braun said. “I am truly humbled and grateful to have been nominated.”

Braun is the fourth doctor or researcher at Dana-Farber named a Next Gen Innovator.